Pioneering Dry Eye Treatments

Eyedetec Medical ensures a unique continuum of care for dry-eye patients

THE CLINICAL CHALLENGE

A Tsunami of Dry Eye Disease Patients Resulting from the Digital Revolution

IMPACT OF DIGITAL INTERFACE ON BLINKING

Natural mechanism, essential for ocular surface health

Reduction from 15 to 5/7 times per minute

eyedetec old woman

DIGITAL EYE STRAIN

Dry eye symptoms and other internal symptoms

Estimated prevalence +50% with digital user

eyedetec man

A recent Gartner poll showed that 48% of employees will likely work remotely at least part of the time after COVID-19 versus 30% before the pandemic.

Dry Eye Disease & Meibomian Gland Dysfunction are Prevalent, with Poor Treatment Options

eyedetec treatment

Highly Prevalent

One of the most common conditions leading patients to see an eye doctor 1

eyedetec negative finance

Negative Financial Impact

On patients and society, projected to be $7.8B by 2025 2

eyedetec eye

Major Impact on Quality of Life

Persistent Pain, Tearing, Contact Lens Failure, Impaired Vision

eyedetec analytics

Incidence Growing

Global increase among all age groups3

No Cure at Present Available

1 Clin Ophthalmol. 2/19; 13: 225–232
2 Transparency Market Research, 1/18
3 AARP report, 11/15

TARGET MARKET AND POTENTIAL

Key Factors Driving the Dry Eye Disease Market

eyedetec cataract

REFRACTIVE CATARACT SURGERY

Pre-op ocular surface critical to outcomes

eyedetec lens

CONTACT LENS INTOLERANCE

30% of patients stop using contacts due to dry eye

eyedete aging

AGING POPULATION

Dry Eye increases with age 25% of population > 50 yrs

eyedetec tech

INCREASED USE OF TECH

Increased screen time leads to decrease frequency of blinking

A PLATFORM FOR CONTINUUM DRY EYE DISEASE CARE

Ensuring unique continuum of DED care

eyedetec ded care treatment

Novel, patented technology - Eye Lipid Mobilizer

eyedetec pre treatment
eyedetec treatment film

DUAL MECHANISMS OF ACTION

Patented Resonant Frequency Stimulation (RFS) with Warming, induces

Liquefaction & Mobilization of Meibum (oil)

Why Invest in Eyedetec?

Currently raising Series A funding

Management Team

eyedetec barry linder

Barry J Linder, MD, MS

President & CEO

30+ years in ophthalmology as a practitioner and executive - Permanente Medical Group, Promedix, SpecialtyMD, Ventro, ConforMIS (NASDAQ: CFMS), Imaging Therapeutics, Clarity Medical Systems

eyedetec thomas dunlap

Thomas Dunlap

Global Business Advisor

Former CEO, Chairman and Board of Directors roles in global Ophthalmic Global Ophthalmic businesses
Senior Executive roles at Mynosys, HOYA Surgical Optics, Bausch+ Lomb, Allergan Medical Optics

eyedetec shareef

Shareef Mahdavi

Strategic Marketing

30+ years in ophthalmic devices; respected marketing expert, author and speaker in global ophthalmology community
Deep experience in product positioning, value proposition refinement and brand building

eyedetec anselm

Anselm Leung

CFO

30+ years in financial services - Executive positions: Merrill Lynch, Shearson Lehman, Salomon Brothers, Montgomery Securities, and BioAsia Investments LLC

eyedetec james

James Dippo

R&D

25 years in R&D with focus on thermal engineering
Executive positions: National Renewable Energy Laboratory, TDA Research

eyedetec john

John Kang

RQ&C

20+ years in QA/RA - medical device, drug-device combination, robotics and implantable
Boston Scientific, Affymetrix, Invuity, Stryker, Nektar Therapeutics, Hansen Medical, Hologic

eyedetec ronald

Ronald Linder

Operations

30+ years in quality engineering and manufacturing
McDonald Aircraft Corp., HON Industries, U.S. Navy Civil Engineer Corps, General Foods Corp, and Motorola

Scientific Advisory Board

  • Daniel Durrie, MD
  • John Hovanesian, MD
  • Laura Periman, MD
  • Randall Fuerst, OD
  • Paul Karpecki, OD
  • John Sheppard, MD
  • Leslie O’Dell, OD
  • Vance Thompson, MD